Study on synthesis of thalidomide analogues and their bioactivities; Inhibition on iNOS pathway and cytotoxic effects

Chao Bin Yeh, Pen Yuan Lin, Jin Ming Hwang, Chi Jung Su, Ying Tung Yeh, Shun Fa Yang, Ming Chih Chou

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Synthetic thalidomide analogues (compounds 1-35), including phenylphthalimide, pyridylphthalimide, aminobenzylphthalimide, and diphenylazophthalimide, were tested for their cytotoxic effects on human cancer cell lines Hep2 (Human Larynx Carcinoma Cells), HL-60 (Human Myeloid Leukemia Cells), NUGC (Human Gastric Carcinoma Cells), and HONE-1 (Human Nasopharyngeal Carcinoma Cells) because the incidence rate is more prominent in Asian countries than in Western countries. Compounds 17, 27, 28, and 35 were found to have antitumor activity in Hep2 and HL-60 cell lines. Compounds 2, 4, 15, 17, 19, 20, 23, and 27 can inhibit nitric oxide (NO) synthase activity by more than 90%. These thalidomide analogues were found to be potent inducible nitric oxide synthase (iNOS) inhibitors, and the iNOS inhibiting potential of compounds 17 and 27 might be an advantage for anticancer therapy. In conclusion, inhibition of NO synthesis is a new development in cancer therapy for now and in the future. We modified the structures of the thalidomide analogues to have a stronger anticancer effect and a good therapeutic effect.

Original languageEnglish
Pages (from-to)953-963
Number of pages11
JournalMedicinal Chemistry Research
Volume21
Issue number7
DOIs
Publication statusPublished - Jul 2012

Fingerprint

Thalidomide
Nitric Oxide Synthase Type II
Bioactivity
Cells
HL-60 Cells
Carcinoma
Cell Line
Myeloid Leukemia
Therapeutic Uses
Myeloid Cells
Larynx
Nitric Oxide Synthase
Neoplasms
Stomach
Nitric Oxide
Incidence
Therapeutics

Keywords

  • Nitric oxide synthase inhibitors
  • Thalidomide
  • Thalidomide analogues

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Organic Chemistry

Cite this

Study on synthesis of thalidomide analogues and their bioactivities; Inhibition on iNOS pathway and cytotoxic effects. / Yeh, Chao Bin; Lin, Pen Yuan; Hwang, Jin Ming; Su, Chi Jung; Yeh, Ying Tung; Yang, Shun Fa; Chou, Ming Chih.

In: Medicinal Chemistry Research, Vol. 21, No. 7, 07.2012, p. 953-963.

Research output: Contribution to journalArticle

Yeh, Chao Bin ; Lin, Pen Yuan ; Hwang, Jin Ming ; Su, Chi Jung ; Yeh, Ying Tung ; Yang, Shun Fa ; Chou, Ming Chih. / Study on synthesis of thalidomide analogues and their bioactivities; Inhibition on iNOS pathway and cytotoxic effects. In: Medicinal Chemistry Research. 2012 ; Vol. 21, No. 7. pp. 953-963.
@article{3ce0cbae833f4ddd83583bf70a95d18e,
title = "Study on synthesis of thalidomide analogues and their bioactivities; Inhibition on iNOS pathway and cytotoxic effects",
abstract = "Synthetic thalidomide analogues (compounds 1-35), including phenylphthalimide, pyridylphthalimide, aminobenzylphthalimide, and diphenylazophthalimide, were tested for their cytotoxic effects on human cancer cell lines Hep2 (Human Larynx Carcinoma Cells), HL-60 (Human Myeloid Leukemia Cells), NUGC (Human Gastric Carcinoma Cells), and HONE-1 (Human Nasopharyngeal Carcinoma Cells) because the incidence rate is more prominent in Asian countries than in Western countries. Compounds 17, 27, 28, and 35 were found to have antitumor activity in Hep2 and HL-60 cell lines. Compounds 2, 4, 15, 17, 19, 20, 23, and 27 can inhibit nitric oxide (NO) synthase activity by more than 90{\%}. These thalidomide analogues were found to be potent inducible nitric oxide synthase (iNOS) inhibitors, and the iNOS inhibiting potential of compounds 17 and 27 might be an advantage for anticancer therapy. In conclusion, inhibition of NO synthesis is a new development in cancer therapy for now and in the future. We modified the structures of the thalidomide analogues to have a stronger anticancer effect and a good therapeutic effect.",
keywords = "Nitric oxide synthase inhibitors, Thalidomide, Thalidomide analogues",
author = "Yeh, {Chao Bin} and Lin, {Pen Yuan} and Hwang, {Jin Ming} and Su, {Chi Jung} and Yeh, {Ying Tung} and Yang, {Shun Fa} and Chou, {Ming Chih}",
year = "2012",
month = "7",
doi = "10.1007/s00044-011-9603-7",
language = "English",
volume = "21",
pages = "953--963",
journal = "Medicinal Chemistry Research",
issn = "1054-2523",
publisher = "Birkhause Boston",
number = "7",

}

TY - JOUR

T1 - Study on synthesis of thalidomide analogues and their bioactivities; Inhibition on iNOS pathway and cytotoxic effects

AU - Yeh, Chao Bin

AU - Lin, Pen Yuan

AU - Hwang, Jin Ming

AU - Su, Chi Jung

AU - Yeh, Ying Tung

AU - Yang, Shun Fa

AU - Chou, Ming Chih

PY - 2012/7

Y1 - 2012/7

N2 - Synthetic thalidomide analogues (compounds 1-35), including phenylphthalimide, pyridylphthalimide, aminobenzylphthalimide, and diphenylazophthalimide, were tested for their cytotoxic effects on human cancer cell lines Hep2 (Human Larynx Carcinoma Cells), HL-60 (Human Myeloid Leukemia Cells), NUGC (Human Gastric Carcinoma Cells), and HONE-1 (Human Nasopharyngeal Carcinoma Cells) because the incidence rate is more prominent in Asian countries than in Western countries. Compounds 17, 27, 28, and 35 were found to have antitumor activity in Hep2 and HL-60 cell lines. Compounds 2, 4, 15, 17, 19, 20, 23, and 27 can inhibit nitric oxide (NO) synthase activity by more than 90%. These thalidomide analogues were found to be potent inducible nitric oxide synthase (iNOS) inhibitors, and the iNOS inhibiting potential of compounds 17 and 27 might be an advantage for anticancer therapy. In conclusion, inhibition of NO synthesis is a new development in cancer therapy for now and in the future. We modified the structures of the thalidomide analogues to have a stronger anticancer effect and a good therapeutic effect.

AB - Synthetic thalidomide analogues (compounds 1-35), including phenylphthalimide, pyridylphthalimide, aminobenzylphthalimide, and diphenylazophthalimide, were tested for their cytotoxic effects on human cancer cell lines Hep2 (Human Larynx Carcinoma Cells), HL-60 (Human Myeloid Leukemia Cells), NUGC (Human Gastric Carcinoma Cells), and HONE-1 (Human Nasopharyngeal Carcinoma Cells) because the incidence rate is more prominent in Asian countries than in Western countries. Compounds 17, 27, 28, and 35 were found to have antitumor activity in Hep2 and HL-60 cell lines. Compounds 2, 4, 15, 17, 19, 20, 23, and 27 can inhibit nitric oxide (NO) synthase activity by more than 90%. These thalidomide analogues were found to be potent inducible nitric oxide synthase (iNOS) inhibitors, and the iNOS inhibiting potential of compounds 17 and 27 might be an advantage for anticancer therapy. In conclusion, inhibition of NO synthesis is a new development in cancer therapy for now and in the future. We modified the structures of the thalidomide analogues to have a stronger anticancer effect and a good therapeutic effect.

KW - Nitric oxide synthase inhibitors

KW - Thalidomide

KW - Thalidomide analogues

UR - http://www.scopus.com/inward/record.url?scp=84861860275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861860275&partnerID=8YFLogxK

U2 - 10.1007/s00044-011-9603-7

DO - 10.1007/s00044-011-9603-7

M3 - Article

VL - 21

SP - 953

EP - 963

JO - Medicinal Chemistry Research

JF - Medicinal Chemistry Research

SN - 1054-2523

IS - 7

ER -